Takeda Hit With $885 Million Verdict Over Generic Drug Delay Scheme
Medical FraudBy Ruth Anselmi
A federal jury in Boston found Takeda liable for blocking generic competition to its constipation drug Amitiza — the first pay-for-delay antitrust verdict against a pharma company in U.S. class-action history.












